研究论文
Trastuzumab Deruxtecan and Sacituzumab Govitecan for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Mengwei Zhang, Gengwei Huo, Zhenzhen Liu, Min Yan
Henan Cancer Hospital Tianjin Medical University Cancer Institute and Hospital
来源Clinical Therapeutics
年份2025
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
210
226
关键指标
2
被引次数 · OpenAlex
0.84
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 26%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
36
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学HER2/EGFR in Cancer Research
Cancer Treatment and Pharmacology · Advanced Breast Cancer Therapies
参考文献 36
Health state utilities for non small cell lung cancer
被引 405Beenish Nafees, Megan Stafford, Sonia Gavriel · Health and Quality of Life Outcomes · 2008
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
被引 1,540Nadia Howlader, Sean F. Altekruse, Christopher I. Li · JNCI Journal of the National Cancer Institute · 2014
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma
被引 152Xiaomin Wan, Yucong Zhang, Chongqing Tan · JAMA Oncology · 2019
此处列出前 3 条
引用本文 2
Efficacy and safety of sacituzumab govitecan in hormone receptor–positive metastatic breast cancer: A systematic review and meta-analysis
被引 0Ali Kaan Güren, Muhammed Fatıh Kırcalı, Murat Sarı · Journal of Oncology Pharmacy Practice · 2026
Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2− advanced breast cancer in China
被引 0Weiwei Huang, Cijuan Li, Yuanqing Huang · Frontiers in Pharmacology · 2026
按被引量排序，此处列出前 3 条